<DOC>
	<DOCNO>NCT01276431</DOCNO>
	<brief_summary>An open label , multi-centre , prospective age-group-controlled study evaluate efficacy safety buprenorphine transdermal patch subject chronic , moderate severe osteoarthritis pain hip and/or knee .</brief_summary>
	<brief_title>Norspan Efficacy Safety Among Elderly Subjects</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>Summary Criteria Inclusion : 1 . Males female age 5060 ≥ 75 year . 2 . Subjects clinical diagnosis osteoarthritis knee and/or hip include fulfilment ACRcriteria radiographic evidence old one year . 3 . Subjects moderate severe pain , confirm BS11 score ≥ 4 pain average last seven day Screening Phase primary OAsite Baseline Visit . Summary Criteria Exclusion : 1 . Subjects record &lt; 4 average Screening Phase BS11 scale . 2 . Subjects treat highpotent opioid analgesic ( e.g . morphine , fentanyl , oxycodone , methadone , hydromorphone , ketobemidone , buprenorphine ) osteoarthritis pain . 3 . Subjects treat regular dose &gt; 1 week tramadol , codeine dextropropoxyphene within 1 month screen visit . 4 . Subjects require NSAID treatment ( except aspirin cardiovascular indication ) cox2inhibitors study period . 5 . Subjects history , ongoing , chronic condition ( ) , addition osteoarthritis , require frequent analgesic therapy ( e.g . frequent headache , frequent migraine , gout , rheumatoid arthritis ) . 6 . Subjects schedule surgery would fall within study period . 7 . Subjects currently abuse substance alcohol , subject , opinion Investigator , demonstrate addictive substance abuse behaviour . 8 . Subjects cancer ( except basal cell carcinoma ) history cancer last 5 year ( except treat basal cell carcinoma ) . 9 . Untreated depression psychiatric disorder way participation study may , opinion Investigator , pose unacceptable risk subject . 10 . Subjects currently take hypnotic , anxiolytic central nervous system depressant , Investigator 's opinion , may pose risk additional CNS depression study medication . 11 . Subjects currently take adjuvant analgesic antidepressant anticonvulsant . 12 . Dermatological disorder nonintact skin relevant patch application site precludes proper placement and/or rotation patch placement . 13 . Subjects receive intraarticular steroid injection within 6 week prior Screening Visit subject require steroid treatment ( oral , intramuscular , intravenous , intraarticular , epidural corticosteroid injection ) study period . 14 . Subjects joint evacuation 6 week prior Screening Visit study . 15 . Subjects currently take monoamine oxidase inhibitor ( MAOI 's ) take MAOI 's within 2 week Screening Visit .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>